Serial No.: 09/943,138
Applicant: Wallace K. DYER
Filed: August 30, 2001
Title: Methods and Compositions for Tissue Augmentation
Page: 5

REMARKS

With entry of this amendment, Claims 1-19 are pending. Claims 1-5 and 7-17 have been amended. Support for these amendments can be found on page 7, line 14, page 9 lines 10-14 and page 10 lines 11-13 and 26-29. No new matter has been added by these amendments.

Early and favorable consideration is earnestly solicited. If the Examiner believes there are other issues that can be resolved by telephone interview, or that there are any informalities remaining in the application which may be corrected by Examiner's Amendment, a telephone call to the undersigned attorney at (404) 815-6500 is respectfully solicited.

Respectfully submitted,

KILPATRICK STOCKTON, LLP

By Janina A. Malone
Reg. No. 47,768

KILPATRICK STOCKTON, LLP
1100 Peachtree St.
Suite 2800
Atlanta, GA 30309-4530
Phone: (404) 815-6500
Fax: (404) 815-6555
Atty Docket: 43076/257892 (04118-0104)

Received from < > at 12/13/02 5:42:15 PM [Eastern Standard Time]

Serial No.: 09/943,138
Applicant: Wallace K. DYER
Filed: August 30, 2001
Title: Methods and Compositions for Tissue Augmentation
Page: 6

MARKED COPY OF AMENDMENTS

Amendments to the Claims:

1. (Amended) A biphasic injectable composition comprising: [for tissue volume replacement]

[a] solid polymer particles, wherein the solid polymer particles are mechanically stable and are suspended in a liquid carrier substrate [phase; and a carrier substrate phase].

2. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles are [polymer phase is] made from micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

3. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles are [polymer phase is] made from at least two of micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

Received from < > at 12/13/02 5:42:15 PM [Eastern Standard Time]

4. (Amended) The composition of Claim 1, wherein the liquid carrier substrate phase is selected from polyvinylpyrrolidone [("PVP")], silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.

5. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles [polymer phase comprises] comprise micronized expanded polytetrafluoroethelene ("e-PTFE") particles.

7. (Amended) The composition of Claim 1, wherein the liquid carrier substrate phase is [PVP] polyvinylpyrrolidone.

8. (Amended) The composition of Claim 7, wherein the [PVP] polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

9. (Amended) The composition of Claim 7, wherein the [PVP] polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

10. (Amended) The composition of Claim 7, wherein the [PVP] polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

11. (Amended) The composition of Claim 7, wherein the [PVP] polyvinylpyrrolidone comprises a K value of 17.

12. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer [phase comprises] particles comprise e-PTFE; and

the carrier substrate [phase] comprises [PVP] polyvinylpyrrolidone.

Received from < > at 12/13/02 5:42:15 PM [Eastern Standard Time]

13. (Amended) The composition of Claim 12 wherein the e-PTFE and the PVP are combined at a ratio of approximately 3:2 [PVP] polyvinylpyrrolidone to e-PTFE by weight.

14. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles [carrier substrate phase comprises] comprise micronized polydioxanone particles ranging in size from approximately 65 to 1000 micrometers.

15. (Amended) A method for tissue augmentation comprising:

injecting a biphasic injectable composition comprising:

[a]solid polymer particles wherein the solid polymer particles are mechanically stable and are suspended in a liquid carrier substrate.

16. (Amended) The method of Claim 15, wherein the mechanically stable solid polymer particles are [polymer phase is] made from micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

17. (Amended) The method of Claim 15, wherein the liquid carrier substrate [phase] is selected from polyvinylpyrrolidone [("PVP")], silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, water or autologous plasma.

Received from < > at 12/13/02 5:42:15 PM [Eastern Standard Time]